25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Seoul Pharma Co. Ltd
Buy, Hold or Sell?

Let's analyze Seoul Pharma Co. Ltd together

I guess you are interested in Seoul Pharma Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Seoul Pharma Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Seoul Pharma Co. Ltd

I send you an email if I find something interesting about Seoul Pharma Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Seoul Pharma Co. Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Seoul Pharma Co. Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
28.1%

What is your share worth?

Current worth
₩3,381.74
Expected worth in 1 year
₩3,419.24
How sure are you?
46.9%

+ What do you gain per year?

Total Gains per Share
₩37.51
Return On Investment
1.1%

For what price can you sell your share?

Current Price per Share
₩3,495.00
Expected price per share
₩2,970 - ₩3,665
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Seoul Pharma Co. Ltd (5 min.)




Live pricePrice per Share (EOD)
₩3,495.00

2.2. Growth of Seoul Pharma Co. Ltd (5 min.)




Is Seoul Pharma Co. Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$27.6m$23.2m$4m14.8%

How much money is Seoul Pharma Co. Ltd making?

Current yearPrevious yearGrowGrow %
Making money$142.1k$820k-$677.9k-477.0%
Net Profit Margin1.6%9.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Seoul Pharma Co. Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Seoul Pharma Co. Ltd?

Welcome investor! Seoul Pharma Co. Ltd's management wants to use your money to grow the business. In return you get a share of Seoul Pharma Co. Ltd.

First you should know what it really means to hold a share of Seoul Pharma Co. Ltd. And how you can make/lose money.

Speculation

The Price per Share of Seoul Pharma Co. Ltd is ₩3,495. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Seoul Pharma Co. Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Seoul Pharma Co. Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,381.74. Based on the TTM, the Book Value Change Per Share is ₩9.38 per quarter. Based on the YOY, the Book Value Change Per Share is ₩435.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Seoul Pharma Co. Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.020.0%0.010.0%0.070.0%-0.020.0%-0.020.0%
Usd Book Value Change Per Share0.020.0%0.010.0%0.300.0%-0.030.0%0.070.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.0%0.010.0%0.300.0%-0.030.0%0.080.0%
Usd Price Per Share2.22-2.48-3.09-4.50-6.02-
Price to Earnings Ratio33.99-14.03-51.38--15.91--115.71-
Price-to-Total Gains Ratio135.95-3,589.47-177.37-680.99-340.14-
Price to Book Ratio0.94-1.06-1.67-2.62-2.93-
Price-to-Total Gains Ratio135.95-3,589.47-177.37-680.99-340.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.4465
Number of shares408
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.01-0.03
Usd Total Gains Per Share0.01-0.03
Gains per Quarter (408 shares)2.68-13.33
Gains per Year (408 shares)10.71-53.33
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101112-55-63
2021124-110-116
3032236-166-169
4043347-221-222
5054459-276-275
60645611-331-328
70756713-386-381
80867815-442-434
90968917-497-487
10010710019-552-540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%7.05.00.058.3%9.011.00.045.0%12.020.00.037.5%12.020.00.037.5%
Book Value Change Per Share3.01.00.075.0%7.05.00.058.3%10.010.00.050.0%15.017.00.046.9%15.017.00.046.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%3.00.017.015.0%9.00.023.028.1%9.00.023.028.1%
Total Gains per Share3.01.00.075.0%7.05.00.058.3%10.010.00.050.0%15.017.00.046.9%15.017.00.046.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Seoul Pharma Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--23.3179.376+149%435.168-95%-48.320+307%105.679-78%
Book Value Per Share--3381.7353338.762+1%2843.798+19%2753.956+23%3180.879+6%
Current Ratio--2.4161.553+56%1.876+29%1.518+59%1.722+40%
Debt To Asset Ratio--0.4190.398+5%0.475-12%0.534-22%0.515-19%
Debt To Equity Ratio--0.7210.661+9%1.069-33%1.315-45%1.010-29%
Dividend Per Share----0%-0%1.638-100%2.372-100%
Enterprise Value--8549833230.00015587618691.250-45%33585680970.000-75%49659564417.750-83%68712382981.094-88%
Eps--23.31717.414+34%100.481-77%-31.636+236%-29.936+228%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.1660.293-43%0.655-75%1.091-85%1.518-89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap40749253500.000+9%36960041230.00041317711706.250-11%51490451750.000-28%74980985391.250-51%100331936963.281-63%
Net Profit Margin--0.0210.016+36%0.093-77%-0.067+418%-0.056+364%
Operating Margin----0%-0%0.005-100%-0.0020%
Operating Ratio--0.7081.225-42%0.921-23%0.691+3%0.993-29%
Pb Ratio1.033+9%0.9371.062-12%1.667-44%2.621-64%2.929-68%
Pe Ratio37.473+9%33.98814.035+142%51.380-34%-15.905+147%-115.713+440%
Price Per Share3495.000+9%3170.0003543.750-11%4416.250-28%6431.000-51%8605.313-63%
Price To Free Cash Flow Ratio----41.6950%8.853-100%-7.1880%-88.3430%
Price To Total Gains Ratio149.891+9%135.9523589.466-96%177.373-23%680.994-80%340.137-60%
Quick Ratio---0.289-100%1.240-100%0.957-100%1.119-100%
Return On Assets--0.0040.003+29%0.018-78%-0.006+255%-0.005+230%
Return On Equity--0.0070.005+33%0.034-80%-0.021+411%-0.015+319%
Total Gains Per Share--23.3179.376+149%435.168-95%-46.682+300%108.051-78%
Usd Book Value--27600109.60027249380.218+1%23209723.154+19%22476458.553+23%25960789.057+6%
Usd Book Value Change Per Share--0.0160.007+149%0.305-95%-0.034+307%0.074-78%
Usd Book Value Per Share--2.3672.337+1%1.991+19%1.928+23%2.227+6%
Usd Dividend Per Share----0%-0%0.001-100%0.002-100%
Usd Enterprise Value--5984883.26110911333.084-45%23509976.679-75%34761695.092-83%48098668.087-88%
Usd Eps--0.0160.012+34%0.070-77%-0.022+236%-0.021+228%
Usd Free Cash Flow---162544.363-100%405553.148-100%1002856.904-100%538848.294-100%
Usd Market Cap28524477.450+9%25872028.86128922398.194-11%36043316.225-28%52486689.774-51%70232355.874-63%
Usd Price Per Share2.447+9%2.2192.481-11%3.091-28%4.502-51%6.024-63%
Usd Profit--190302.000142127.062+34%820077.855-77%-258198.611+236%-244324.698+228%
Usd Revenue--8996358.0009286794.892-3%8910234.177+1%8779807.338+2%8540280.616+5%
Usd Total Gains Per Share--0.0160.007+149%0.305-95%-0.033+300%0.076-78%
 EOD+4 -3MRQTTM+17 -13YOY+12 -195Y+19 -1410Y+16 -16

3.3 Fundamental Score

Let's check the fundamental score of Seoul Pharma Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1537.473
Price to Book Ratio (EOD)Between0-11.033
Net Profit Margin (MRQ)Greater than00.021
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than12.416
Debt to Asset Ratio (MRQ)Less than10.419
Debt to Equity Ratio (MRQ)Less than10.721
Return on Equity (MRQ)Greater than0.150.007
Return on Assets (MRQ)Greater than0.050.004
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Seoul Pharma Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.933
Ma 20Greater thanMa 503,408.500
Ma 50Greater thanMa 1003,663.400
Ma 100Greater thanMa 2003,879.000
OpenGreater thanClose3,480.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Seoul Pharma Co. Ltd

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and menopausal syndrome. The company also provides Ator for high blood pressure treatment; Flavel to treat stroke; Axated, a peptic ulcer medication; Crestin to treat hyperlipidemia; and Weltmin and Fendigene for the treatment of obesity. It also owns patents to orally dispersible films. The company was founded in 1976 and is headquartered in Cheongju-si, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 10:51:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Seoul Pharma Co. Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 2.1% means that ₩0.02 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Seoul Pharma Co. Ltd:

  • The MRQ is 2.1%. The company is making a profit. +1
  • The TTM is 1.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.1%TTM1.6%+0.6%
TTM1.6%YOY9.3%-7.8%
TTM1.6%5Y-6.7%+8.3%
5Y-6.7%10Y-5.6%-1.1%
4.3.1.2. Return on Assets

Shows how efficient Seoul Pharma Co. Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.4% Return on Assets means that Seoul Pharma Co. Ltd generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.4%TTM0.3%+0.1%
TTM0.3%YOY1.8%-1.5%
TTM0.3%5Y-0.6%+0.9%
5Y-0.6%10Y-0.5%-0.1%
4.3.1.3. Return on Equity

Shows how efficient Seoul Pharma Co. Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Equity means Seoul Pharma Co. Ltd generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.5%+0.2%
TTM0.5%YOY3.4%-2.9%
TTM0.5%5Y-2.1%+2.7%
5Y-2.1%10Y-1.5%-0.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Seoul Pharma Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Seoul Pharma Co. Ltd is operating .

  • Measures how much profit Seoul Pharma Co. Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y0.5%-0.5%
5Y0.5%10Y-0.2%+0.7%
4.3.2.2. Operating Ratio

Measures how efficient Seoul Pharma Co. Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.71 means that the operating costs are ₩0.71 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.708. The company is efficient in keeping operating costs low. +1
  • The TTM is 1.225. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.708TTM1.225-0.517
TTM1.225YOY0.921+0.304
TTM1.2255Y0.691+0.535
5Y0.69110Y0.993-0.302
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Seoul Pharma Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Seoul Pharma Co. Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.42 means the company has ₩2.42 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 2.416. The company is able to pay all its short-term debts. +1
  • The TTM is 1.553. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.416TTM1.553+0.864
TTM1.553YOY1.876-0.323
TTM1.5535Y1.518+0.035
5Y1.51810Y1.722-0.204
4.4.3.2. Quick Ratio

Measures if Seoul Pharma Co. Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.289-0.289
TTM0.289YOY1.240-0.951
TTM0.2895Y0.957-0.668
5Y0.95710Y1.119-0.161
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Seoul Pharma Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Seoul Pharma Co. Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Seoul Pharma Co. Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.42 means that Seoul Pharma Co. Ltd assets are financed with 41.9% credit (debt) and the remaining percentage (100% - 41.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.419. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.398. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.419TTM0.398+0.021
TTM0.398YOY0.475-0.077
TTM0.3985Y0.534-0.137
5Y0.53410Y0.515+0.019
4.5.4.2. Debt to Equity Ratio

Measures if Seoul Pharma Co. Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 72.1% means that company has ₩0.72 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.721. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.661. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.721TTM0.661+0.060
TTM0.661YOY1.069-0.408
TTM0.6615Y1.315-0.654
5Y1.31510Y1.010+0.305
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Seoul Pharma Co. Ltd generates.

  • Above 15 is considered overpriced but always compare Seoul Pharma Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 33.99 means the investor is paying ₩33.99 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Seoul Pharma Co. Ltd:

  • The EOD is 37.473. Based on the earnings, the company is overpriced. -1
  • The MRQ is 33.988. Based on the earnings, the company is overpriced. -1
  • The TTM is 14.035. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD37.473MRQ33.988+3.485
MRQ33.988TTM14.035+19.953
TTM14.035YOY51.380-37.345
TTM14.0355Y-15.905+29.940
5Y-15.90510Y-115.713+99.808
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Seoul Pharma Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-41.695+41.695
TTM-41.695YOY8.853-50.548
TTM-41.6955Y-7.188-34.507
5Y-7.18810Y-88.343+81.155
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Seoul Pharma Co. Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.94 means the investor is paying ₩0.94 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Seoul Pharma Co. Ltd:

  • The EOD is 1.033. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.937. Based on the equity, the company is cheap. +2
  • The TTM is 1.062. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.033MRQ0.937+0.096
MRQ0.937TTM1.062-0.125
TTM1.062YOY1.667-0.605
TTM1.0625Y2.621-1.559
5Y2.62110Y2.929-0.308
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets67,838,936
Total Liabilities28,410,208
Total Stockholder Equity39,428,728
 As reported
Total Liabilities 28,410,208
Total Stockholder Equity+ 39,428,728
Total Assets = 67,838,936

Assets

Total Assets67,838,936
Total Current Assets27,462,888
Long-term Assets40,376,048
Total Current Assets
Total Current Assets  (as reported)27,462,888
Total Current Assets  (calculated)0
+/- 27,462,888
Long-term Assets
Long-term Assets  (as reported)40,376,048
Long-term Assets  (calculated)0
+/- 40,376,048

Liabilities & Shareholders' Equity

Total Current Liabilities11,364,801
Long-term Liabilities17,045,407
Total Stockholder Equity39,428,728
Total Current Liabilities
Total Current Liabilities  (as reported)11,364,801
Total Current Liabilities  (calculated)0
+/- 11,364,801
Long-term Liabilities
Long-term Liabilities  (as reported)17,045,407
Long-term Liabilities  (calculated)0
+/- 17,045,407
Total Stockholder Equity
Total Stockholder Equity (as reported)39,428,728
Total Stockholder Equity (calculated)0
+/- 39,428,728
Other
Common Stock Shares Outstanding 11,659
Net Working Capital 16,098,087



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-03-312015-12-312015-09-302015-06-302013-09-302013-06-302013-03-312012-09-30
> Total Assets 
0
0
0
0
86,541,000
82,223,000
82,675,000
81,205,000
89,177,376
86,932,322
87,724,378
87,744,643
90,572,594
90,568,819
92,224,783
92,402,792
90,424,491
70,890,348
95,400,020
91,642,443
78,682,719
65,087,339
63,869,186
62,068,031
63,619,312
62,250,025
61,074,602
61,968,767
62,759,477
62,428,070
63,733,040
63,314,652
63,177,770
63,305,407
64,309,004
67,838,936
67,838,93664,309,00463,305,40763,177,77063,314,65263,733,04062,428,07062,759,47761,968,76761,074,60262,250,02563,619,31262,068,03163,869,18665,087,33978,682,71991,642,44395,400,02070,890,34890,424,49192,402,79292,224,78390,568,81990,572,59487,744,64387,724,37886,932,32289,177,37681,205,00082,675,00082,223,00086,541,0000000
   > Total Current Assets 
20,080,406
20,607,624
22,851,586
22,417,233
32,033,000
28,284,000
30,022,000
28,723,000
43,091,236
40,505,427
40,331,832
40,364,369
43,703,965
44,109,046
45,636,057
45,562,113
44,281,566
25,218,659
49,839,357
47,895,298
35,538,483
25,932,819
24,782,516
22,752,491
24,473,358
24,813,908
24,007,745
25,064,913
26,339,562
26,011,923
27,674,266
26,054,421
26,045,663
25,608,951
27,176,766
27,462,888
27,462,88827,176,76625,608,95126,045,66326,054,42127,674,26626,011,92326,339,56225,064,91324,007,74524,813,90824,473,35822,752,49124,782,51625,932,81935,538,48347,895,29849,839,35725,218,65944,281,56645,562,11345,636,05744,109,04643,703,96540,364,36940,331,83240,505,42743,091,23628,723,00030,022,00028,284,00032,033,00022,417,23322,851,58620,607,62420,080,406
       Cash And Cash Equivalents 
0
0
0
0
10,902,000
8,058,000
9,376,000
8,099,000
3,971,645
4,426,740
4,045,707
3,243,830
5,071,144
4,733,959
8,647,946
7,909,034
5,699,431
7,665,368
16,777,275
34,608,956
23,028,199
15,057,335
13,294,787
11,997,061
13,873,501
13,820,215
0
0
0
11,728,409
13,205,276
7,249,240
6,906,480
6,573,631
7,803,850
0
07,803,8506,573,6316,906,4807,249,24013,205,27611,728,40900013,820,21513,873,50111,997,06113,294,78715,057,33523,028,19934,608,95616,777,2757,665,3685,699,4317,909,0348,647,9464,733,9595,071,1443,243,8304,045,7074,426,7403,971,6458,099,0009,376,0008,058,00010,902,0000000
       Short-term Investments 
0
0
0
0
500,000
0
0
0
500,000
0
0
0
2,000,000
3,500,000
1,000,000
0
0
0
0
0
3,181
3,181
3,181
3,181
0
0
0
0
0
0
0
2,790,600
2,670,000
3,090,000
2,976,000
0
02,976,0003,090,0002,670,0002,790,60000000003,1813,1813,1813,181000001,000,0003,500,0002,000,000000500,000000500,0000000
       Net Receivables 
11,473,465
10,754,783
12,044,944
12,467,347
15,066,000
13,909,000
14,545,000
13,509,000
25,922,150
30,984,103
31,240,219
31,466,232
30,412,661
29,496,891
30,890,776
31,235,171
32,422,103
8,041,377
28,895,654
3,964,867
3,678,961
3,157,115
3,626,770
4,025,659
4,392,073
4,437,221
4,696,461
5,045,253
5,181,889
4,924,704
4,930,168
4,701,856
5,377,418
5,041,444
4,863,311
0
04,863,3115,041,4445,377,4184,701,8564,930,1684,924,7045,181,8895,045,2534,696,4614,437,2214,392,0734,025,6593,626,7703,157,1153,678,9613,964,86728,895,6548,041,37732,422,10331,235,17130,890,77629,496,89130,412,66131,466,23231,240,21930,984,10325,922,15013,509,00014,545,00013,909,00015,066,00012,467,34712,044,94410,754,78311,473,465
       Inventory 
4,861,252
4,688,623
4,334,714
5,260,062
5,447,000
6,080,000
5,997,000
6,545,000
4,669,789
4,922,212
4,806,647
5,381,262
5,653,453
6,037,792
4,692,161
6,066,053
5,668,524
9,395,089
3,849,262
9,052,372
7,663,540
7,454,279
7,702,879
6,624,625
6,126,830
6,466,422
6,606,649
7,103,519
7,781,640
9,198,086
9,255,320
11,168,311
10,950,268
10,695,611
11,371,337
0
011,371,33710,695,61110,950,26811,168,3119,255,3209,198,0867,781,6407,103,5196,606,6496,466,4226,126,8306,624,6257,702,8797,454,2797,663,5409,052,3723,849,2629,395,0895,668,5246,066,0534,692,1616,037,7925,653,4535,381,2624,806,6474,922,2124,669,7896,545,0005,997,0006,080,0005,447,0005,260,0624,334,7144,688,6234,861,252
       Other Current Assets 
324,800
149,394
43,895
41,507
85,000
4,000
67,000
333,000
7,986,465
20,445
97,951
151,033
167,867
235,170
311,598
277,736
211,088
46,556
233,375
239,288
1,013,725
52,080
54,726
22,274
25,721
10,969
8,336
8,563
9,385
15,953
6,238
6,536
1,028
1,628
39,928
0
039,9281,6281,0286,5366,23815,9539,3858,5638,33610,96925,72122,27454,72652,0801,013,725239,288233,37546,556211,088277,736311,598235,170167,867151,03397,95120,4457,986,465333,00067,0004,00085,00041,50743,895149,394324,800
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,416,147
36,058,774
37,260,231
37,132,107
37,696,456
37,132,238
40,376,048
40,376,04837,132,23837,696,45637,132,10737,260,23136,058,77436,416,14700000000000000000000000000000
       Property Plant Equipment 
32,583,928
38,522,965
40,770,840
41,160,154
0
0
0
0
42,505,209
42,756,529
42,269,884
42,258,174
41,786,354
41,275,647
41,013,905
40,489,770
39,985,079
41,398,416
40,461,737
40,705,578
40,174,321
35,475,682
35,271,922
34,798,024
34,243,693
34,054,736
33,834,388
33,668,076
33,175,057
30,676,023
30,555,369
30,844,622
30,742,132
31,330,088
30,859,109
0
030,859,10931,330,08830,742,13230,844,62230,555,36930,676,02333,175,05733,668,07633,834,38834,054,73634,243,69334,798,02435,271,92235,475,68240,174,32140,705,57840,461,73741,398,41639,985,07940,489,77041,013,90541,275,64741,786,35442,258,17442,269,88442,756,52942,505,209000041,160,15440,770,84038,522,96532,583,928
       Long Term Investments 
0
0
0
0
475,000
483,000
494,000
503,000
268,896
278,897
287,762
299,108
309,250
319,527
328,392
340,222
350,712
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000350,712340,222328,392319,527309,250299,108287,762278,897268,896503,000494,000483,000475,0000000
       Intangible Assets 
0
0
0
0
0
0
0
0
1,166,670
926,945
914,074
908,226
925,565
961,253
956,060
947,665
1,043,898
938,623
904,567
929,940
990,666
1,107,780
1,284,410
2,059,356
2,384,809
865,109
948,021
904,287
891,902
881,348
871,996
861,432
851,458
841,724
832,071
0
0832,071841,724851,458861,432871,996881,348891,902904,287948,021865,1092,384,8092,059,3561,284,4101,107,780990,666929,940904,567938,6231,043,898947,665956,060961,253925,565908,226914,074926,9451,166,67000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,886
0
0
-1
0
0
0
000-1003,88600000000000000000000000000000
> Total Liabilities 
0
0
0
0
51,753,000
48,488,000
49,147,000
48,096,000
38,761,532
33,076,170
35,608,681
36,243,993
40,310,375
40,254,893
41,951,071
41,706,593
39,613,983
42,439,805
44,109,802
64,607,736
43,507,531
36,234,870
37,416,055
36,945,722
39,349,070
43,292,371
42,341,123
43,272,418
43,451,295
27,006,391
24,827,352
24,323,212
24,616,762
24,741,266
25,152,136
28,410,208
28,410,20825,152,13624,741,26624,616,76224,323,21224,827,35227,006,39143,451,29543,272,41842,341,12343,292,37139,349,07036,945,72237,416,05536,234,87043,507,53164,607,73644,109,80242,439,80539,613,98341,706,59341,951,07140,254,89340,310,37536,243,99335,608,68133,076,17038,761,53248,096,00049,147,00048,488,00051,753,0000000
   > Total Current Liabilities 
16,224,986
14,280,993
12,726,238
12,988,156
24,640,000
22,498,000
23,878,000
24,479,000
18,449,503
18,438,867
19,816,854
20,854,441
27,191,292
14,020,842
15,018,755
13,149,206
16,583,302
26,728,526
15,862,634
37,197,619
15,953,788
18,446,589
32,946,678
32,671,178
25,109,854
28,804,688
28,788,224
29,795,947
29,724,831
13,890,764
11,606,492
11,038,191
20,933,670
20,531,905
20,854,809
11,364,801
11,364,80120,854,80920,531,90520,933,67011,038,19111,606,49213,890,76429,724,83129,795,94728,788,22428,804,68825,109,85432,671,17832,946,67818,446,58915,953,78837,197,61915,862,63426,728,52616,583,30213,149,20615,018,75514,020,84227,191,29220,854,44119,816,85418,438,86718,449,50324,479,00023,878,00022,498,00024,640,00012,988,15612,726,23814,280,99316,224,986
       Short-term Debt 
0
0
0
0
41,185,000
37,900,000
37,770,000
37,123,000
133,332
12,218,303
5,438,904
12,351,531
19,962,444
6,889,597
3,426,652
0
4,000,000
4,000,000
2,000,000
2,000,000
2,000,000
2,000,000
2,000,000
2,000,000
4,000,000
4,000,000
4,000,000
4,000,000
4,000,000
4,000,000
2,000,000
0
0
0
0
0
000002,000,0004,000,0004,000,0004,000,0004,000,0004,000,0004,000,0002,000,0002,000,0002,000,0002,000,0002,000,0002,000,0004,000,0004,000,00003,426,6526,889,59719,962,44412,351,5315,438,90412,218,303133,33237,123,00037,770,00037,900,00041,185,0000000
       Short Long Term Debt 
0
0
0
0
41,185,000
37,900,000
37,770,000
37,123,000
133,332
12,218,303
5,438,904
12,351,531
19,962,444
6,889,597
3,426,652
0
5,314,843
0
0
0
0
0
0
0
0
0
0
0
18,592,618
4,000,000
2,000,000
0
10,000,000
10,000,000
10,000,000
0
010,000,00010,000,00010,000,00002,000,0004,000,00018,592,618000000000005,314,84303,426,6526,889,59719,962,44412,351,5315,438,90412,218,303133,33237,123,00037,770,00037,900,00041,185,0000000
       Accounts payable 
3,163,985
3,166,790
3,579,486
3,491,266
3,177,000
2,607,000
3,188,000
2,897,000
2,583,092
3,009,944
3,245,873
3,973,840
3,659,226
2,462,963
3,713,684
4,017,645
2,400,747
0
0
0
0
0
0
0
0
0
0
0
0
2,994,863
2,078,296
3,022,699
2,927,964
2,830,741
3,457,498
0
03,457,4982,830,7412,927,9643,022,6992,078,2962,994,8630000000000002,400,7474,017,6453,713,6842,462,9633,659,2263,973,8403,245,8733,009,9442,583,0922,897,0003,188,0002,607,0003,177,0003,491,2663,579,4863,166,7903,163,985
       Other Current Liabilities 
1,526,564
2,639,964
1,970,951
1,206,484
1,341,000
1,360,000
1,452,000
1,827,000
6,374,350
2,023,494
1,468,285
1,523,545
1,298,080
1,784,738
1,928,764
2,282,673
2,116,462
0
0
0
0
0
0
0
0
0
0
0
0
1,367,276
1,341,188
1,424,782
1,300,010
1,442,724
1,421,466
0
01,421,4661,442,7241,300,0101,424,7821,341,1881,367,2760000000000002,116,4622,282,6731,928,7641,784,7381,298,0801,523,5451,468,2852,023,4946,374,3501,827,0001,452,0001,360,0001,341,0001,206,4841,970,9512,639,9641,526,564
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,115,627
13,220,860
13,285,021
3,683,092
4,209,361
4,297,327
17,045,407
17,045,4074,297,3274,209,3613,683,09213,285,02113,220,86013,115,62700000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,857,251
11,578,132
20,317,948
24,565,598
24,613,690
14,670,662
1,212,808
1,103,073
10,987,658
10,871,107
10,754,200
10,655,808
10,595,994
10,481,281
10,391,737
10,324,498
0
0
0
0
000010,324,49810,391,73710,481,28110,595,99410,655,80810,754,20010,871,10710,987,6581,103,0731,212,80814,670,66224,613,69024,565,59820,317,94811,578,13214,857,2510000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-41,185,000
-37,900,000
-37,770,000
-37,123,000
-133,332
-12,218,303
-5,438,904
-12,351,531
-19,962,444
-6,889,597
-3,426,652
0
-4,000,000
-4,000,000
-2,000,000
-2,000,000
-2,000,000
-2,000,000
-2,000,000
-2,000,000
-4,000,000
-4,000,000
-4,000,000
-4,000,000
-4,000,000
-3,052,613
-1,174,596
755,443
636,574
955,885
836,839
0
0836,839955,885636,574755,443-1,174,596-3,052,613-4,000,000-4,000,000-4,000,000-4,000,000-4,000,000-2,000,000-2,000,000-2,000,000-2,000,000-2,000,000-2,000,000-4,000,000-4,000,0000-3,426,652-6,889,597-19,962,444-12,351,531-5,438,904-12,218,303-133,332-37,123,000-37,770,000-37,900,000-41,185,0000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
216,904
253,644
248,878
12,964
232,282
267,292
0
0267,292232,28212,964248,878253,644216,90400000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
1,522,000
1,858,000
924,000
835,000
396,652
355,395
317,683
281,936
246,190
210,443
174,698
138,952
103,205
70,459
40,713
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000040,71370,459103,205138,952174,698210,443246,190281,936317,683355,395396,652835,000924,0001,858,0001,522,0000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
50,415,844
53,856,152
52,115,697
51,500,650
50,262,219
50,313,926
50,273,712
50,696,199
50,810,508
28,450,543
51,290,218
27,034,707
35,175,188
28,852,469
26,453,131
25,122,309
24,270,242
18,957,654
18,733,479
18,696,350
19,308,183
35,421,679
38,905,688
38,991,440
38,561,007
38,564,141
39,156,868
39,428,728
39,428,72839,156,86838,564,14138,561,00738,991,44038,905,68835,421,67919,308,18318,696,35018,733,47918,957,65424,270,24225,122,30926,453,13128,852,46935,175,18827,034,70751,290,21828,450,54350,810,50850,696,19950,273,71250,313,92650,262,21951,500,65052,115,69753,856,15250,415,84400000000
   Common Stock
3,150,000
3,150,000
3,428,885
3,428,885
16,427,000
16,427,000
16,427,000
16,427,000
4,179,232
4,192,272
4,211,478
4,242,750
4,242,750
4,242,750
4,242,750
4,242,750
4,242,750
4,242,750
4,242,750
4,242,750
4,262,262
4,262,262
4,262,262
4,262,262
4,262,262
4,262,262
4,262,262
4,262,262
4,262,262
5,829,660
5,829,660
5,829,660
0
0
0
0
00005,829,6605,829,6605,829,6604,262,2624,262,2624,262,2624,262,2624,262,2624,262,2624,262,2624,262,2624,262,2624,242,7504,242,7504,242,7504,242,7504,242,7504,242,7504,242,7504,242,7504,242,7504,211,4784,192,2724,179,23216,427,00016,427,00016,427,00016,427,0003,428,8853,428,8853,150,0003,150,000
   Retained Earnings Total Equity000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,599,163
33,358,694
36,181,655
35,037,878
35,434,352
33,674,821
35,434,352
35,434,352
35,434,352
33,674,821
29,519,351
29,519,351
29,519,351
47,246,730
29,592,019
29,592,019
0
0
0
0
000029,592,01929,592,01947,246,73029,519,35129,519,35129,519,35133,674,82135,434,35235,434,35235,434,35233,674,82135,434,35235,037,87836,181,65533,358,69431,599,1630000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
4,920
4,920
4,920
4,920
0
0
0
0
1,759,530
1,759,531
1,759,531
1,759,530
1,759,531
1,759,531
1,759,530
1,759,531
1,759,531
1,759,531
1,759,531
1,759,531
0
0
0
0
0
0
5,915,001
5,915,001
5,915,001
0
0
0
0
0
0
0
00000005,915,0015,915,0015,915,0010000001,759,5311,759,5311,759,5311,759,5311,759,5311,759,5301,759,5311,759,5311,759,5301,759,5311,759,5311,759,53000004,9204,9204,9204,920



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue52,458,517
Cost of Revenue-20,870,999
Gross Profit31,587,51831,587,518
 
Operating Income (+$)
Gross Profit31,587,518
Operating Expense-51,245,740
Operating Income1,212,777-19,658,222
 
Operating Expense (+$)
Research Development3,141,367
Selling General Administrative20,371,406
Selling And Marketing Expenses0
Operating Expense51,245,74023,512,773
 
Net Interest Income (+$)
Interest Income383,637
Interest Expense-442,512
Other Finance Cost-0
Net Interest Income-58,875
 
Pretax Income (+$)
Operating Income1,212,777
Net Interest Income-58,875
Other Non-Operating Income Expenses0
Income Before Tax (EBT)4,043,7181,212,777
EBIT - interestExpense = -442,512
3,517,329
3,959,841
Interest Expense442,512
Earnings Before Interest and Taxes (EBIT)04,486,230
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax4,043,718
Tax Provision-526,389
Net Income From Continuing Ops3,517,3293,517,329
Net Income3,517,329
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net058,875
 

Technical Analysis of Seoul Pharma Co. Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Seoul Pharma Co. Ltd. The general trend of Seoul Pharma Co. Ltd is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Seoul Pharma Co. Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Seoul Pharma Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3,575 < 3,655 < 3,665.

The bearish price targets are: 2,970.

Tweet this
Seoul Pharma Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Seoul Pharma Co. Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Seoul Pharma Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Seoul Pharma Co. Ltd. The current macd is -61.65919766.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Seoul Pharma Co. Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Seoul Pharma Co. Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Seoul Pharma Co. Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Seoul Pharma Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSeoul Pharma Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Seoul Pharma Co. Ltd. The current adx is 21.42.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Seoul Pharma Co. Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Seoul Pharma Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Seoul Pharma Co. Ltd. The current sar is 3,043.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Seoul Pharma Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Seoul Pharma Co. Ltd. The current rsi is 50.93. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Seoul Pharma Co. Ltd Daily Relative Strength Index (RSI) ChartSeoul Pharma Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Seoul Pharma Co. Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Seoul Pharma Co. Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Seoul Pharma Co. Ltd Daily Stochastic Oscillator ChartSeoul Pharma Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Seoul Pharma Co. Ltd. The current cci is 73.15.

Seoul Pharma Co. Ltd Daily Commodity Channel Index (CCI) ChartSeoul Pharma Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Seoul Pharma Co. Ltd. The current cmo is 11.89.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Seoul Pharma Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartSeoul Pharma Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Seoul Pharma Co. Ltd. The current willr is -12.5.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Seoul Pharma Co. Ltd Daily Williams %R ChartSeoul Pharma Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Seoul Pharma Co. Ltd.

Seoul Pharma Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Seoul Pharma Co. Ltd. The current atr is 156.48.

Seoul Pharma Co. Ltd Daily Average True Range (ATR) ChartSeoul Pharma Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Seoul Pharma Co. Ltd. The current obv is 26,422,939.

Seoul Pharma Co. Ltd Daily On-Balance Volume (OBV) ChartSeoul Pharma Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Seoul Pharma Co. Ltd. The current mfi is 37.73.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Seoul Pharma Co. Ltd Daily Money Flow Index (MFI) ChartSeoul Pharma Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Seoul Pharma Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Seoul Pharma Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Seoul Pharma Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.933
Ma 20Greater thanMa 503,408.500
Ma 50Greater thanMa 1003,663.400
Ma 100Greater thanMa 2003,879.000
OpenGreater thanClose3,480.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Seoul Pharma Co. Ltd with someone you think should read this too:
  • Are you bullish or bearish on Seoul Pharma Co. Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Seoul Pharma Co. Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Seoul Pharma Co. Ltd

I send you an email if I find something interesting about Seoul Pharma Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Seoul Pharma Co. Ltd.

Receive notifications about Seoul Pharma Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.